Taking drug holidays might keep prostate cancer under control longer
NCT ID NCT02415621
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 26 times
Summary
This study tested whether taking the drug abiraterone on an on-and-off schedule could help men with advanced prostate cancer respond to the drug for a longer time. Nineteen men with metastatic castration resistant prostate cancer who already had a good response to abiraterone were enrolled. The goal was to see if this flexible dosing could delay the cancer from becoming resistant while maintaining quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.